Imaging services firm NMR of America enjoyed buoyant financialresults for its 1995 fiscal year (end-March). The Murray Hill,NJ, company said net revenue and net profit were at the highestlevel in the company's history. NMR of America posted annual net
Imaging services firm NMR of America enjoyed buoyant financialresults for its 1995 fiscal year (end-March). The Murray Hill,NJ, company said net revenue and net profit were at the highestlevel in the company's history.
NMR of America posted annual net revenues of $18 million, up15% compared to the $15.6 million brought in the year before.Net income surged to $2.4 million, an increase of 78% comparedto net income of $1.4 million in 1994. Net income for the yearincluded non-recurring items that resulted in a net benefit of$539,000. The company's net income for the year was a record,even if the benefit were excluded from its results.
NMR of America's numbers were aided by the acquisition of threeIllinois imaging centers, in Oak Lawn, Libertyville and Des Plaines.In addition, net income was improved by the reduction in minorityinterests due to the firm's purchase of limited partnership interestsin seven of its centers.
The company is proceeding with its plan to merge with MorganMedical (SCAN 4/12/95). NMR of America filed a preliminary jointproxy and prospectus with the Securities and Exchange Commissionin May.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.